CDR-Life announces early clinical data demonstrating pharmacodynamic activity of CDR404: Zurich, Switzerland Saturday, October 25, 2025, 18:00 Hrs [IST] CDR-Life, Inc, a biotechno ...
At exposure levels associated with its clinical dose of 150 mg once daily, GLPG3667 showed inhibition of the IFN-α, and IL-23 pathways, comparable to the expected inhibition for the currently approved ...
Clinical Trials Arena on MSN
ADARx doses first subject in Phase III trial of ADX-324 for HAE
The Phase III placebo-controlled, randomised, double-blind study is evaluating ADX-324's efficacy in adults with HAE.
The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.
Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy; JADE101 is an investigational, p ...
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting ...
EV25 was generally well-tolerated and demonstrated a good safety profile, with no observable dose-dependent safety trends.
Chemists at Université de Montréal have developed "signaling cascades" made with DNA molecules to report and quantify the ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...
Patients with mild to moderate asthma receiving one dose of an anti-thymic stromal lymphopoietin monoclonal antibody ...
Aquestive Therapeutics leverages its PharmFilm platform to develop Anaphylm, a sublingual epinephrine film, a $1B+ market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback